iX Biopharma Ltd.
http://www.ixbiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From iX Biopharma Ltd.
Asia Deal Watch: Astellas Looks To Next-Gen AAV Vectors Despite Gene Therapy Clinical Setbacks
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
European Biotechs Resort to Layoffs
Since redundancies in Europe are expensive and politically sensitive, companies have tended, where possible, to find other ways of cutting costs. The prolonged biotech winter is leaving many European biotechs with few options besides layoffs, however.
Proteomics Firms Turn to IT for Database Upgrade
Proteomics companies don't want to be seen as database providers, a low-valuation model once pursued by Celera and Incyte. So companies like Myriad Genetics and Oxford GlycoSciences have spun out their database businesses into JVs with IT partners, which provide cash and technology. Both partners benefit: biotechs get valued as budding drug developers and retain access to these tools, while IT companies get a foot in the door of the life sciences markets into which they wish to expand their products and services.
UCL Ventures (University College London)
Spin-out activity at UCL Ventures was jump-started by the success of one company, SR Pharma, during the late nineties. The tech transfer office now takes advantage of London's status as a business and financial center to find and develop new entrepreneurs, and continues to benefit from UK government seed funds.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice